Sitaxentan

Sitaxentan

Sitaxentan (marketed under the brand name Thelin) was an oral medication used to treat pulmonary arterial hypertension (PAH). It belonged to a class of medications known as endothelin receptor antagonists, which help to relax the blood vessels in the lungs, making it easier for the heart to pump blood through them.

Mechanism of Action

Sitaxentan worked by selectively blocking the endothelin receptor type A (ET_A), which is predominantly responsible for the vasoconstrictive and proliferative effects of endothelin-1 (ET-1), a potent vasoconstrictor. By inhibiting this receptor, sitaxentan reduced pulmonary vascular resistance and improved cardiac output in patients with PAH.

Clinical Use

Sitaxentan was approved for the treatment of pulmonary arterial hypertension in several countries, including Canada, Australia, and the European Union. It was indicated for use in patients with Class II or III symptoms of PAH to improve exercise capacity and delay clinical worsening. However, it was not approved for use in the United States.

Adverse Effects

The use of sitaxentan was associated with several potential adverse effects, including liver enzyme elevations, peripheral edema, nasal congestion, and anemia. Due to the risk of liver toxicity, patients on sitaxentan required regular monitoring of liver function tests.

Withdrawal from Market

In December 2010, Pfizer, the manufacturer of sitaxentan, voluntarily withdrew the drug from the market due to concerns over its safety profile, particularly the risk of potentially fatal liver injury. The decision to withdraw sitaxentan was based on a review of ongoing clinical trials and post-marketing reports.

Impact on Treatment of PAH

The withdrawal of sitaxentan from the market left a gap in the treatment options available for PAH patients. However, other endothelin receptor antagonists, such as bosentan and ambrisentan, continue to be used in the management of PAH, offering alternative treatment options for patients affected by this condition.